Development of a hospital Deprescribing Implementation Framework:A focus group study with geriatricians and Pharmacists by Scott, Sion et al.
1
Age and Ageing 2019; 00: 1–9
doi: 10.1093/ageing/afz133
Published electronically
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Geriatrics Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is
properly cited. For commercial re-use, please contact journals.permissions@oup.com
QUALITATIVE PAPER
Development of a hospital deprescribing
implementation framework: A focus group study
with geriatricians and pharmacists
Sion Scott1,2, Michael J. Twigg1, Allan Clark3, Carol Farrow2, Helen May4, Martyn Patel4,
Johanna Taylor5, David J. Wright1, Debi Bhattacharya1
1School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK
2Pharmacy Department, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK
3Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK
4Older People’s Medicine Department, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK
5Department of Health Sciences, University of York, York YO10 5DD, UK
Address correspondence to: Sion Scott, School of Pharmacy, University of East Anglia, Norwich, NR4 7TJ, UK, Tel: +44 (0)1603
591996. Email: sion.scott@uea.ac.uk
Abstract
Background: over 50% of older people in hospital are prescribed a pre-admission medicine that is potentially inappropriate;
however, deprescribing by geriatricians and pharmacists is limited. This study aimed to characterise geriatricians’ and
pharmacists’ barriers and enablers to deprescribing in hospital. It also intended to develop a framework of intervention
components to facilitate implementation of hospital deprescribing.
Methods: fifty-four geriatricians and pharmacists representing four UK hospitals attended eight focus groups. We designed
a topic guide to invite discussions about barriers and enablers to deprescribing. After thematic analysis, themes were mapped
to the theoretical domains framework (TDF), enabling prioritisation of domains for behaviour change. We then identified
evidence-based intervention components for changing behaviour within prioritised TDF domains.
Results: geriatricians and pharmacists described several deprescribing enablers in the hospital setting including alignment
with their role and generalist knowledge, and routine patient monitoring. Five prioritised TDF domains represent the key
barriers and enabler: patient and caregiver attachment to medication (social influence); perceptions that deprescribing is
riskier than continuing to prescribe (beliefs about consequences); pharmacists’ working patterns limiting capacity to support
deprescribing (environmental context and resources); deprescribing being a low hospital priority (goals) and incentives to
deprescribe (reinforcement). Prioritised TDF domains aligned with 44 evidence-based intervention components to address
the barriers and enabler to hospital deprescribing.
Conclusion: the behavioural determinants and their associated intervention components provide a hospital deprescribing
implementation framework (hDIF). Intervention components should be selected from the hDIF to provide a theory and
evidence-based intervention tailored to hospital contexts.
Keywords: inappropriate medication, deprescriptions, behaviour change, secondary care, qualitative, older people
Key points
• Barriers and enablers to deprescribing are context-specific; interventions targeting deprescribing behaviour should reflect
this.
• This study provides a hospital deprescribing implementation framework of 44 intervention components.
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Background
Over 50% of older people in hospital are prescribed a pre-
admission medicine that is potentially inappropriate, pre-
disposing them to adverse outcomes including morbidity,
rehospitalisation and mortality [1]. This has led to calls for
deprescribing of potentially inappropriate medicines (PIMs)
in hospital [2]. A 2018 evaluation of hospital deprescribing
reported only 4% of patients had a pre-admission medicine
deprescribed [3], suggesting a need to change practitioner
behaviour to facilitate routine deprescribing in hospital.
An understanding of whose behaviour needs changing
and their barriers and enablers to this behaviour is key to
behaviour change [4]. Primary care barriers to deprescribing
include limited skills and knowledge to deprescribe and
perceived resistance of patients and carers [5]. Emerging
guidelines regarding when and how to deprescribe medicine
groups may address knowledge and skill barriers [6–9].
Theory-informed interventions to encourage patient partici-
pation in deprescribing may address the barrier of their resis-
tance [10]. Access to geriatricians and pharmacists working
in hospitals is a primary care enabler to deprescribing [5].
Geriatricians and pharmacists may be the most appropri-
ate practitioners to deprescribe in hospitals; however, their
barriers and enablers to deprescribing are yet to be fully
understood [5]. This may explain the failure of hospital
deprescribing interventions to achieve clinically significant
reductions in PIMs [11]. Some primary care barriers and
enablers may be relevant to geriatricians and pharmacists
in hospital [5]. However, others that are specific to the
hospital context may remain unknown and also vary between
hospitals [12].
The importance of applying theory to understand the
processes of behaviour change is widely recognised [13].
The theoretical domains framework (TDF) is an integrative
framework of behaviour change theories for developing
interventions [14]. It comprises 14 domains representing
determinants of behaviour, for example the “Knowledge”
domain refers to “an awareness of the existence of something”
and “Environmental context and resources” refers to
“circumstance of a person’s situation or environment that
discourages or encourages the desired behaviour” [14].
Identifying the important domains for the target behaviour
provides the theoretical understanding required to develop
an intervention [14]. The 14 TDF domains are linked
to a taxonomy of behaviour change techniques (BCTs)
[15], which are the “building blocks” of behaviour change
interventions. The TDF has been applied extensively to
develop interventions targeting practitioners’ behaviours
including promoting uptake of a screening tool in geriatric
oncology [16].
In the present qualitative study, we used the TDF to
understand geriatricians’ and pharmacists’ barriers and
enablers to deprescribing in hospital. We explored whether
these barriers and enablers differed between hospital
contexts. Additionally, for the TDF domains identified as
important for deprescribing, we identified relevant BCTs for
selecting to develop a theory and evidence-based hospital
deprescribing intervention for older people.
Methods
Ethical approval
Ethical and governance approvals were obtained from
the Faculty of Medicine and Health Sciences Research
Ethics Committee, University of East Anglia (Reference:
2017/2018—59) and the United Kingdom Health Research
Authority (IRAS project ID: 231262), respectively.
Design
We adopted an exploratory qualitative approach to under-
stand the barriers and enablers to deprescribing experienced
and perceived by geriatricians and pharmacists. We selected
a focus group study design and employed thematic analysis
to explore barriers and enablers inductively. We used the
TDF as a framework to identify BCTs to address barriers and
enablers [4]. We used the consolidated criteria for reporting
qualitative research checklist to guide reporting (Appendix 1,
Supplementary data are available in Age and Ageing online).
Setting
We selected four hospitals across three English counties,
two of which were 1,000 and 1,200 bed teaching hospitals
with four and six geriatric wards, respectively, and two
were 450 and 550 bed district general hospitals each with
three geriatric wards. These were used to explore barriers
and enablers of deprescribing for older people and capture
any variation arising from differing resources and patient
populations associated with these different sample settings.
Sample
We included senior geriatricians and pharmacists from the
four hospitals based on practice experience (minimum 6 and
4 years respectively). We invited pharmacists from all clinical
specialities in recognition of the range of responsibilities
often adopted despite speciality.
We planned eight focus groups to explore similarities and
differences in attitudes between geriatricians and pharma-
cists, and identify hospital characteristics that might influ-
ence deprescribing. Each hospital site hosted two focus
groups: one with geriatricians and one with pharmacists,
with five to eight participants each (n = 40 to 64 in total).
We followed the principles for deciding saturation in
theory-based qualitative studies outlined by Francis et al.
[17]. However, as a study objective was to explore any
differences between district general and teaching hospital
contexts, an a priori decision was made to convene all eight
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Recruitment
We invited all eligible potential participants by email via
a gatekeeper. The email comprised an information leaflet
(including study aims) and focus group scheduling arrange-
ments. Potential participants completed an online expression
of interest survey requesting: professional group, gender,
hospital seniority grade and prescribing authority status
(pharmacists only). We purposively sampled potential par-
ticipants to maximise variation in demographics. We sought
a mixture of prescribing and non-prescribing pharmacists to
explore differences in attitudes arising from the acquisition
of additional prescribing competencies. We remunerated
employing hospitals for participants’ time commitment to
the research.
Data collection
Researchers, geriatricians, pharmacists and patient and care-
giver representatives developed a semi-structured topic guide
(Appendix 2, Supplementary data are available in Age and
Ageing online) informed by the deprescribing literature.
Guiding questions were designed to elicit views regarding the
following:
1. Perception of existing deprescribing practice
2. Barriers to increasing deprescribing practice
3. Enablers of increasing deprescribing practice
We adapted standard questions to elicit barriers and
enablers to deprescribing within all 14 TDF domains and
used them as probes to ensure full coverage of the TDF in
discussions. We piloted the topic guide with geriatrician and
pharmacist collaborators (n = 3) who were representative of
the target focus group population; they did not participate
in the study. The purpose of the piloting was to check
understanding of questions, ascertain the depth of data
generated from the guide and assess the feasibility of covering
all TDF domains in the allotted time.
We collected focus group data between February and
May 2018. We obtained consent at the beginning of each
focus group and convened them in meeting rooms at the
hospitals. Two academic pharmacist researchers (SS and
DB) facilitated, made field notes during the discussions
and audio recorded the events. SS completed training in
qualitative research methodology and the principles and
practice of behaviour change research prior to the study. DB
has extensive experience of conducting qualitative research
underpinned by behaviour change theory.
Analysis
A research administrator transcribed verbatim focus group
recordings that were then anonymised and checked for accu-
racy by a researcher (SS). We imported data into NVivo
11 (QSR International, Melbourne, Australia) to facilitate
the following three phases of analysis: (i) thematic analysis
to identify determinants of deprescribing in hospital, (ii)
mapping of all identified determinants of deprescribing to
the TDF and (iii) prioritising TDF domains for targeting in
a deprescribing intervention and identify the BCTs linked to
these domains. We shared all processes of the analysis with
the study management group, which included geriatricians,
clinical pharmacists and patient and caregiver representa-
tives, to enhance transparency and validity of interpretation.
Phase 1: thematic analysis
We initially analysed data through the customary steps
of thematic analysis to ensure resultant themes were not
restricted to the pre-defined TDF domains [18]. After data
familiarisation (step 1), SS coded inductively for barriers
and enablers to deprescribing (step 2). Two researchers expe-
rienced in qualitative (MJT) and behaviour change (DB)
research reviewed codes and refined through discussion.
Three researchers (SS, MJT and DB) then categorised the
inductive coding and subsequent themes were extracted,
reviewed and defined (steps 3–5). Inductive coding and
thematic analysis were undertaken concurrently after each
focus group. Geriatrician and pharmacist transcripts were
initially coded separately and grouped into categories as
appropriate. Categories for both professional groups were
then combined to form overarching themes. At all times
of data abstraction, constant referral back to transcripts,
hospital contexts and codes was undertaken to unsure that
the analysis remained true to, and reflected appropriately,
the developing themes.
We considered emergent themes in the context of
the existing literature; we comprehensively reported and
described themes representing novel concepts and briefly
described any themes overlapping with the literature [5].
Phase 2: mapping of all determinants of deprescribing to the TDF
SS and DB re-read the transcripts and mapped inductive
codes from phase 1 to the relevant TDF domain(s). We
used the TDF domain definitions to guide this mapping and
organised coded data within each domain into barriers and
enablers to deprescribing [14]. We compared our mapping
and resolved any disagreements through discussion and refer-
ral to a third researcher experienced in health psychology and
qualitative research (JT).
Phase 3: prioritising TDF domains for targeting in a deprescribing
intervention and identifying the BCTs linked to these domains
The phase 1 thematic analysis provided a contextualised
understanding of the barriers and enablers most important
to participants for effecting deprescribing behaviour change.
We used this information to prioritise the TDF domains
most relevant for a deprescribing intervention. We identified
the relevant domains through consensus discussion between
three researchers (SS, MJT and DB) and confirmed by a
health psychologist (JT).
For each theme, we collated all barriers and enablers
expressed by the collective as exerting a strong impact on
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Table 1. Focus group participant characteristics
Hospital Professional group Number of participants Number with prescribing authority
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hospital 1a Pharmacists 8 (4 female 4 male) 3
Hospital 1a Geriatricians 7 (5 female 2 male) 7
Hospital 2a Pharmacists 7 (7 female) 1
Hospital 2a Geriatricians 8 (3 female 5 male) 8
Hospital 3b Pharmacists 6 (3 female 3 male) 1
Hospital 3b Geriatricians 7 (4 female 3 male) 7
Hospital 4b Pharmacists 5 (2 female 3 male) 1
Hospital 4b Geriatricians 6 (1 female 5 male) 6
aTeaching hospital. bDistrict general hospital.
We prioritised the mapped domain for each of the barriers.
For the enablers, if participants expressed that a change
in the status quo was required, then we prioritised whilst
those enablers already present by virtue of implementing the
intervention in the hospital setting were not prioritised.
For each of the prioritised TDF domains, we identified
all potentially effective BCTs for developing a deprescribing
intervention for older people in hospital. We used the map-
ping table developed by Cane et al. [15], which links BCTs
to TDF domains to inform this process.
Results
Sample
All geriatricians and pharmacists who were purposively sam-
pled participated in the focus groups. Fifty-four participants;
28 geriatricians and 26 pharmacists, participated across the
eight focus groups. Table 1 provides participant character-
istics. The mean (standard deviation) focus group duration
was 55 (5) minutes.
Phase 1: thematic analysis
We identified four themes: (i) role of different professionals;
(ii) the inpatient environment; (iii) consideration of out-
comes and (iv) attitudes towards medicines. Themes were
recurring after the third focus group and no new themes
emerged after the sixth focus group.
In accordance with the planned analysis, themes 1 and
2 represented novel concepts and are therefore compre-
hensively reported with illustrative quotations for contex-
tualisation provided. Themes 3 and 4 are briefly described
because they overlap extensively with the existing primary
care literature, therefore only divergences are highlighted.
There were no discernible differences between participants
from teaching and district general hospitals or prescribing
and non-prescribing pharmacists.
Role of different professionals There was high motivation
to increase deprescribing in hospital; geriatricians and phar-
macists recognised that existing practice was limited and
reactive to harms, rather than proactive to avoid harms.
“I think we do a lot more reactive deprescribing probably and a lot less
proactive deprescribing than we should.” (Pharmacist 2, Hospital 2)
Both professional groups acknowledged that increasing
deprescribing aligned with the generalist nature of their
respective roles and responsibilities. However, the role of
practitioners with a restricted focus, such as therapeutic area
specialists (e.g. cardiology, infectious diseases and surgery),
was described as potentially incompatible with deprescribing
for older people.
Participants indicated that junior healthcare practitioners,
including junior geriatricians and pharmacists, lacked the
required competencies to lead deprescribing. This was a
recognised consequence of insufficient trainee healthcare
practitioner experience and limited education regarding
deprescribing within training programmes.
Whilst the scope for several professional groups working
in hospital to contribute to deprescribing was recognised,
there was consensus that overall responsibility should rest
with one professional group. There was agreement across the
focus groups that geriatricians should assume this overall
responsibility. Furthermore, in the geriatrician focus groups,
many participants expressed confidence in their ability to
weigh up the risks and benefits of deprescribing PIMs to
inform decision-making. For geriatricians therefore, the
main barriers to deprescribing were environmental and
resource factors.
“It’s interesting how all of the barriers to deprescribing are practical rather
than I just don’t know whether I should stop it. So we’re extremely confident
in our ability to decide this is why this is what we should do.” (Geriatrician
5, Hospital 2)
Pharmacists suggested that their skill set aligns with iden-
tifying PIMs and advising on deprescribing, which was
also endorsed by geriatricians. Pharmacists were reluctant to
assume overall responsibility for deprescribing because of an
expressed lack of confidence in decision-making.
“And then it’s just the difficulty of clinical relevance of these medications
and the context of the patient that maybe pharmacists wouldn’t be happy
with. It would have to be somebody who’s feeling happy enough to do it.”
(Pharmacist 2, Hospital 3)
However, existing working patterns and priorities in hospital
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substantial role in deprescribing and was a significant barrier
to them supporting deprescribing in hospital.
“The time that we have on the ward as pharmacists is for discharges,
missed doses if you can do a medication reconciliation great and that’s
about it. The actual clinical review of medicines is squeezed.” (Pharmacist 5,
Hospital 4)
The inpatient environment The patient’s clinical picture,
communication and access to resources were perceived influ-
encers of deprescribing. Both geriatricians and pharmacists
acknowledged that there was scope to increase deprescrib-
ing in hospital. This was complemented by the necessary
resources and capacity available in hospital to safely trial
deprescribing and monitor patients.
“If they’re in hospital they can be monitored more closely when you do stop
the riskier medication and if they’re in for a length of time . . . then there’s
the time to stop medication.” (Pharmacist 5, Hospital 3)
Challenges to deprescribing in the hospital setting were
also acknowledged. Limited information available to hospital
practitioners regarding patients’ medications was raised as
a barrier. Strength, dose and formulation of pre-admission
medications were routinely ascertained by pharmacists by
discussing with patients and accessing electronic medication
records. However, key information required to determine
whether deprescribing is appropriate, such as the reason
why the medication was prescribed and for how long, were
reportedly rarely known.
“You don’t always have all the information in hospital... it’s very difficult
to make that decision. There’s always the risk you might end up stopping
something they really do need. And it might not be obvious that they really
do need it from the information you’ve got in front of you.” (Pharmacist 7,
Hospital 1)
A further barrier to deprescribing was the acute nature of
a hospital admission requiring prioritisation of the patient’s
problems for immediate action. This was confounded by
the patient’s artificial lifestyle whilst in hospital, including
immobility, scheduled meals and medications being man-
aged by healthcare practitioners. These factors were perceived
to distort the assessments undertaken in hospital to inform
long-term deprescribing decisions.
“Things might change so dramatically when they leave hospital, either they’ve
recovered from their sepsis and they need their antihypertensives or they’ve
started eating again and they need more of their gliclazide.” (Geriatrician 5,
Hospital 2)
Participants asserted a clear need to establish a safety net
through sharing information with primary care providers
responsible for ongoing care after patients are discharged
from hospital. It was suggested that such correspondence
could include directions for monitoring for changes that may
indicate re-prescribing was necessary. However, participants
agreed that the existing transfer of information between care
settings was poor and may undermine deprescribing efforts.
“I think we’re very bad at relaying changes to the GPs [primary care
practitioners]. I get a lot of letters from GPs saying this person was discharged
and you stopped this list of medications and then you look at the discharge
letter and there’s no reason why, or sometimes it doesn’t mention it was
stopped at all.” (Geriatrician 5, Hospital 4)
Similarly, pharmacist participants voiced concerns regard-
ing communicating medication changes with patients in
hospital. Barriers identified included patients being unable
to participate in decision-making because of ill health and
deprescribing being regarded by patients as a low priority
relative to the acute condition responsible for the admission.
However, the availability of carers as both sources of medica-
tion information and participants in decision-making were
facilitators.
Participants expressed disappointment about not receiv-
ing feedback on positive outcomes resulting from hospital-
initiated deprescribing once patients were discharged. Both
professional groups recognised the successes of schemes to
incentivise changes in antimicrobial prescribing practice in
the UK hospital setting. This led to suggestions that similar
approaches may also be enablers of deprescribing.
Consideration of outcomes The perceived risks and poten-
tial benefits of deprescribing versus continuing to prescribe
were identified as key influencers of deprescribing behaviour.
Potential patient orientated positive outcomes were a reduc-
tion in medication burden and incidence of adverse drug
events, leading to improved quality of life. A reduction
in unnecessary medication expenditure, reduced treatment
costs associated with adverse drug events and rationalising
use of health resources were proposed healthcare system
benefits. In turn, patient and health system benefits were
perceived to result in individual practitioner benefits, with
geriatricians and pharmacists suggesting that deprescribing
may lead to reduced workloads.
There was divergence in views between geriatrician and
pharmacist participants regarding whether deprescribing was
perceived to carry greater risk than continuing to prescribe.
Pharmacist participants felt that on balance, passively con-
tinuing to prescribe a medicine in the absence of immediate
harm was safer than proactively deprescribing. Conversely,
geriatricians felt that both deprescribing and continuing to
prescribe were active decisions, with no inherent differences
in risk providing both are carefully considered.
Attitudes towards medicines Geriatricians and pharmacists
described patients’, families’, other healthcare practitioners’
and wider societies’ attitudes towards medicines as influ-
encers on their own deprescribing behaviour. Patient and
carer attachment to medication was described as a difficult
barrier to overcome. However, both professional groups
acknowledged that a significant proportion of older people
dislike taking medication and are therefore likely to be
amenable to deprescribing.
Healthcare culture’s attitude towards medication use was
acknowledged as changing in favour of deprescribing, with
the burden of inappropriate medication use now increas-
ingly recognised. Nevertheless, participants felt that this
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Table 2. Summary of barriers and enablers to deprescribing mapped to nine TDF domains
Barrier Enabler TDF domain
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Theme: attitudes towards medicines
Patient and carer attachment to medicationa,b Patient dislike of medicationa,b 6. Social influence
Treatment guidelinesa Primary care respecting hospital decision-makingb
Societal labelling of medicines as “always good”a Deprescribing awarenessb
Theme: consideration of outcomes
Adverse outcomes for patients, practitioners and
hospitalsa,b
Improved outcomes for patients, practitioners and hospitalsa,b 10. Beliefs about consequences
Continuing to prescribe is less risky than
deprescribingb
No difference in risk between prescribing and deprescribinga
Fear of consequences and assuming responsibilitya 14. Emotion
Theme: role of different healthcare professionals
Pharmacists lack confidence to make decisionsa,b Confidence in decision makingb 8. Beliefs about capabilities
Deprescribing education is poora,b Generalist knowledge and broad experiencea,b 1. Knowledge
Hospitals primary role is acute carea Role includes deprescribinga,b 7. Social/professional role and identity
Pharmacists’ existing working patternsa,b Changing working patterns to support deprescribinga,b 5. Environmental context and resources
Theme: the inpatient environment
Deprescribing is not a hospital’s prioritya,b Setting deprescribing goalsa,b 12. Goals
Limited feedback on deprescribing outcomesa Deprescribing incentivea,b 13. Reinforcement
Artificial patient status in hospitala,b Hospitals are well resourced to deprescribea,b 5. Environmental context and resources
Incomplete medication historya,b Opportunity to trial deprescribinga,b
aGeriatrician expressed barrier or enabler. bPharmacist expressed barrier or enabler.
were described as overemphasising prescribing medication
without considering opportunities for deprescribing.
Phase 2: mapping of all determinants of deprescribing to the TDF
All of the inductive codes from the four themes, organ-
ised into the nine mapped TDF domains, according to
whether they were barriers or enablers to deprescribing
(i.e. influencers of deprescribing behaviours) are provided
in Appendix 3, Supplementary data are available in Age
and Ageing online. Codes in the theme “Attitudes towards
medicines” were only mapped to one TDF domain whilst the
remaining three themes incorporated multiple domains. A
summary of barriers and enablers derived from the inductive
codes within each theme, mapped to nine TDF domains, is
provided in Table 2.
Phase 3: prioritising TDF domains for targeting in a deprescribing
intervention and identifying the BCTs linked to these domains
Figure 1 provides the hospital deprescribing implementation
framework (hDIF) of TDF domains prioritised for target-
ing in a novel hospital deprescribing intervention for older
people. For the prioritised domains, the 44 linked BCTs are
listed [15]. The process of selecting from this list of 44 BCTs
according to local contexts is also illustrated in Figure 1, and
examples are provided for five hypothetically selected BCTs
that have been characterised by the research team.
“Social professional role and identity” and “Knowledge”
are not prioritised because whilst these represented strong
enablers, both geriatricians and pharmacists asserted that
deprescribing aligns with existing perceptions of their com-
plementary roles and knowledge. Similarly, “Beliefs about
capabilities” are not represented because both professions
had confidence in their ability to undertake their defined
roles. It can be seen that the “Emotion” domain, which was
exclusively expressed with barriers by pharmacists being fear-
ful of assuming responsibility for any negative consequences
of deprescribing, is not represented. This is in recognition
of participants across both professions agreeing that geriatri-
cians should assume overall responsibility for deprescribing
in hospital.
The three TDF domains of “Social influence”, “Envi-
ronmental Context and Resources” and “Goals” represented
strong barriers to both geriatricians and pharmacists depre-
scribing behaviour and therefore are prioritised for target-
ing. Additionally, for pharmacists, the “Beliefs about conse-
quences” domain is prioritised in recognition of their per-
ception that continuing to prescribe a medication presents
less risk than deprescribing.
The “Reinforcement” domain is prioritised because par-
ticipants expressed a desire for feedback on patient outcomes
and an incentive in order to facilitate deprescribing.
Discussion
Key drivers for implementing hospital deprescribing for
older people are that both geriatricians and pharmacists
perceive it to align with their (Social/professional role and
identity). They are also confident in their existing “Knowl-
edge” and “Beliefs about capabilities” to undertake their
identified roles. This contrasts the ambivalence and per-
ceived additional training needs of primary care physicians
to undertaking this role [5].
A hospital deprescribing intervention for older people
led by geriatricians and supported by pharmacists was the
preferred configuration. For pharmacists to adopt this sup-
portive role, the “Environmental context and resources”
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Figure 1. A hospital deprescribing implementation framework (hDIF) of prioritised TDF domains and linked BCT for developing
a deprescribing intervention targeting the behaviours of geriatricians and pharmacists according to local hospital contexts. ∗BCT
is linked to multiple prioritised TDF domains. ∗∗e.g. Nominal group and Delphi techniques [19]. ∗∗∗Affordable, practical,
effective/cost-effective, acceptable, safe and equitable [20]
patterns aligning with active participation in core clinical
team activity [21, 22].
The evidence suggests that deprescribing is widely acceptable
to patients and carers [23–25], yet geriatricians and pharma-
cists believe there to be resistance. An intervention should
therefore target “Social influences” to address this misalign-
ment between the evidence and practitioners’ beliefs.
The enablers to deprescribing offered by the inpatient
environment such as routine monitoring provide a safe
opportunity to trial deprescribing. Pharmacists were still
concerned that the risks may outweigh the potential benefits
of deprescribing. An intervention should therefore target
pharmacists’ “Beliefs about consequences” to recalibrate their
perceptions of the relative risks and benefits of deprescribing.
The inpatient environment presented the barrier of pri-
oritising acute problems over deprescribing. Targeting the
“Goals” domain to raise the priority of deprescribing in
hospital may be an appropriate solution. Encouragingly,
participants acknowledged the scope to increase deprescrib-
ing in hospital [3]. The proposed enabler of incentivisation
mapped to the “Reinforcement” domain may be an appro-
priate intervention component given that it has previously
demonstrated efficacy in influencing hospital antimicrobial
prescribing behaviours [26].
Sufficient medication information needs to be available
to facilitate deprescribing decision-making, including when
and why a medication was originally prescribed [27]. The
barrier of incomprehensive medication histories extends
across all healthcare settings, prompting calls for routine
documentation of indications and an intended duration
at initial prescribing [28]. Targeting the “Environmental
context and resources” domain through restructuring the
environment may ameliorate some of these effects and
additionally address the barrier of patients being acutely
unwell during periods of the admission. This may take
the form of an outpatient clinic, which provides time to
both gather medication information and for the patients to
recover from their acute illness.
The influencers of whether geriatricians and pharmacists
deprescribe in the hospital setting that requires addressing
are mapped to 44 BCTs. This provides a theory-informed
hospital deprescribing implementation framework (hDIF)
for developing an intervention targeting geriatricians’ and
pharmacists’ behaviour. Patient focussed interventions such
as the EMPOWER educational brochure may complement
this approach through encouraging patient engagement in
deprescribing [10].
Data triangulation from intra and inter-professional con-
vergence around the key issues was frequently observed,
affording confidence in the reliability of findings [29]. The
transferability of barriers and enablers between district gen-
eral and teaching hospitals indicates that the BCTs identified
may be applicable to other hospital contexts [30].
Confining the study to the UK hospital population may
limit the international transferability of findings, particularly
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The required specificity when developing behaviour change
interventions focussed this study on geriatricians and phar-
macists, and therefore the views of other potentially relevant
professionals were not captured. This approach could be
duplicated in other countries and other professional groups
where the deprescribing role is less likely to be assumed by
geriatricians and pharmacists.
The deprescribing research agenda should recognise the
five TDF domains of “Social influence”, “Beliefs about con-
sequences”, “Environmental context and resources”, “Goals”
and “Reinforcement”. The hDIF developed in this study
provides a range of BCTs for developing a hospital depre-
scribing intervention. Future work to select BCTs from the
hDIF according to local contexts may be achieved through
consensus methods structured according to affordability,
practicability, effectiveness/cost-effectiveness, acceptability,
side effects/safety and equity [20].
Supplementary data: Supplementary data mentioned in the
text are available to subscribers in Age and Ageing online.
Acknowledgements We thank participating geriatricians,
pharmacists and gatekeepers for their contribution to this
study. The authors also thank the National Institute for
Health Research Clinical Research Network for assisting
with recruitment.
Declaration of Conflict of Interest: None.
Declaration of Funding: The research was funded by
Pharmacy Research UK (Personal Research Award number:
PRUK-2017-PA2-A).
Sponsor’s role: The sponsor had no role in the design
and conduct of the study; collection, management, analysis,
and interpretation of the data and preparation, review, or
approval of the manuscript.
References
1. Gallagher P, Lang PO, Cherubini A et al. Prevalence of poten-
tially inappropriate prescribing in an acutely ill population of
older patients admitted to six European hospitals. Eur J Clin
Pharmacol 2011; 67: 1175–88.
2. Avery AJ, Coleman JJ. Tackling potentially inappropriate
prescribing. BMJ 2018; 363: k4688.
3. Scott S, Clark A, Farrow C et al. Deprescribing admission
medication at a UK teaching hospital; a report on quantity
and nature of activity. Int J Clin Pharmacol 2018. Oct 1; 40:
991–6.
4. Atkins L, Francis J, Islam R et al. A guide to using
the theoretical domains framework of behaviour change to
investigate implementation problems. Implement Sci 2017;
12: 77.
5. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber
barriers and enablers to minimising potentially inappropriate
medications in adults: a systematic review and thematic syn-
thesis. BMJ Open 2014; 4: e006544.
6. Farrell B, Black C, Thompson W et al. Deprescribing antihy-
perglycemic agents in older persons: evidence-based clinical
practice guideline. Can Fam Physician 2017; Nov. 1, 63:
832–43.
7. Farrell B, Pottie K, Thompson W et al. Deprescribing proton
pump inhibitors: evidence-based clinical practice guideline.
Can Fam Physician 2017; 63: 354–64.
8. Pottie K, Thompson W, Davies S et al. Deprescribing ben-
zodiazepine receptor agonists: evidence-based clinical practice
guideline. Can Fam Physician 2018; 64: 339–51.
9. Bjerre LM, Farrell B, Hogel M et al. Deprescribing antipsy-
chotics for behavioural and psychological symptoms of
dementia and insomnia: evidence-based clinical practice
guideline. Can Fam Physician 2018; 64: 17–27.
10. Martin P, Tannenbaum C. Use of the EMPOWER brochure
to deprescribe sedative-hypnotic drugs in older adults with
mild cognitive impairment. BMC Geriatr 2017; 17: 37.
11. Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact
of deprescribing interventions in older hospitalised patients
on prescribing and clinical outcomes: a systematic review of
randomised trials. Drugs Aging 2018; 35: 303–19.
12. Papanikolaou PN, Christidi GD, Ioannidis JPA. Patient out-
comes with teaching versus nonteaching healthcare: a system-
atic review. PLoS Med 2006; 3: e341.
13. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Pet-
ticrew M. Developing and evaluating complex interventions:
the new Medical Research Council guidance. BMJ 2008; Sep
29; 337:a1655.
14. Cane J, O’Connor D, Michie S. Validation of the theoretical
domains framework for use in behaviour change and imple-
mentation research. Implement Sci 2012; 7: 37.
15. Cane J, Richardson M, Johnston M, Ladha R, Michie S.
From lists of behaviour change techniques (BCTs) to struc-
tured hierarchies: comparison of two methods of develop-
ing a hierarchy of BCTs. Br J Health Psychol 2015; 20:
130–50.
16. Gulasingam P, Haq R, Mascarenhas Johnson A et al. Using
implementation science to promote the use of the G8 screen-
ing tool in geriatric oncology. J Am Geriatr Soc 2019. doi:
10.1111/jgs.15920.
17. Francis JJ, Johnston M, Robertson C et al. What is an adequate
sample size? Operationalising data saturation for theory-based
interview studies. Psychol Health 2010; 25: 1229–45.
18. Braun V, Clarke V. Using thematic analysis in psychology.
Qual Res Psychol 2006; 3: 77–101.
19. McMillan SS, King M, Tully MP. How to use the nominal
group and Delphi techniques. Int J Clin Pharmacol 2016; 38:
655–62.
20. Michie S, Atkins L, West R. The Behaviour Change Wheel: A
Guide to Designing Interventions. 1st edition. Great Britain:
Silverback Publishing, 2014.
21. Béchet C, Pichon R, Giordan A, Bonnabry P. Hospital
pharmacists seen through the eyes of physicians: qualitative
semi-structured interviews. Int J Clin Pharmacol 2016; 38:
1483–96.
22. Makowsky MJ, Schindel TJ, Rosenthal M, Campbell K,
Tsuyuki RT, Madill HM. Collaboration between pharmacists,








niversity of East Anglia user on 11 N
ovem
ber 2019
Development of a hospital deprescribing implementation framework
of working relationships in the inpatient medical setting. J
Interprof Care 2009; 23: 169–84.
23. Okeowo D, Patterson A, Boyd C, Reeve E, Gnjidic D, Todd
A. Clinical practice guidelines for older people with multi-
morbidity and life-limiting illness: what are the implications
for deprescribing? Ther Adv Drug Saf 2018; 9: 619–30.
24. Reeve E, Anthony AC, Kouladjian, O’Donnell L et al. Devel-
opment and pilot testing of the revised patients’ attitudes
towards deprescribing questionnaire for people with cognitive
impairment. Australas J Ageing 2018; 37: E150–4.
25. Sirois C, Ouellet N, Reeve E. Community-dwelling older
people’s attitudes towards deprescribing in Canada. Res Soc
Adm Pharm 2017; 13: 864–70.
26. Islam J, Ashiru-Oredope D, Budd E et al. A national qual-
ity incentive scheme to reduce antibiotic overuse in hos-
pitals: evaluation of perceptions and impact. J Antimicrob
Chemother 2018; 73: 1708–13.
27. Woodward MC. Deprescribing: achieving better health out-
comes for older people through reducing medications. J
Pharm Pract Res 2003; 33: 323–8.
28. Pike H. Deprescribing: the fightback against polypharmacy
has begun. Pharm J 2018; 301: 11.
29. Farmer T, Robinson K, Elliott SJ, Eyles J. Developing and
implementing a triangulation protocol for qualitative health
research. Qual Health Res 2006; 16: 377–94.
30. Smith B. Generalizability in qualitative research: misunder-
standings, opportunities and recommendations for the sport
and exercise sciences. Qual Res Sport Exerc Heal 2018; 10:
137–49.









niversity of East Anglia user on 11 N
ovem
ber 2019
